Table 1 Patient characteristics in the derivation cohort (men with IPF) and the validation cohort (men and women with fibrotic ILD) stratified by DHEAS
From: Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study
|  | Derivation cohort (n = 31) | Validation cohort (n = 238) | ||
|---|---|---|---|---|
DHEASa Lowest quartile | DHEASa 2nd–4th quartiles | DHEASb Lowest quartile | DHEASb 2nd–4th quartiles | |
Sex, men | 8 (100%) | 23 (100%) | 17 (28%) | 89 (50%) |
Age | 69.1 (13.8) | 70.1 (9.1) | 67.5 (10.6) | 62.7 (13.2) |
IPF diagnosis | 8 (100%) | 23 (100%) | 5 (8%) | 38 (21%) |
BMI, kg/m2 | 29.0 (4.4) | 28.0 (4.8) | 28.8 (6.5) | 26.9 (5.0) |
Ever smoker | 4 (50%) | 15 (65%) | 35 (58%) | 112 (63%) |
FVC, %-predicted | 54.8 (16.1) | 65.0 (15.5) | 69.0 (21.6) | 78.6 (16.8) |
FEV1, %-predicted | 65.5 (9.8) | 74.7 (11.7) | 70.1 (21.4) | 80.7 (17.3) |
DLCO, %-predicted | 30.0 (9.8) | 49.4 (15.5) | 46.0 (18.2) | 52.5 (15.4) |
CPI | 63.7 (11.9) | 48.9 (12.5) | 46.8 (15.5) | 41.8 (12.8) |
Nintedanib | 3 (38%) | 12 (52%) | 1 (2%) | 7 (4%) |
Pirfenidone | 3 (38%) | 4 (17%) | 1 (2%) | 7 (4%) |